Hopes of home winner dashed by Tsonga injury

(Reuters) – Hopes of a homegrown winner at this year’s French Open disappeared in the Parisian gloom on Sunday when Jo-Wilfried Tsonga retired injured from his fourth-round clash against Russian Mikhail Youzhny.

Sports

Tsonga, the eighth seed, received treatment to his leg when trailing 5-2 in the opening set and called it a day when Youzhny, the 11th seed, won the following game.

Tsonga spoke to the chair umpire, flung his racket onto his chair and offered Youzhny his hand.

The former Australian Open finalist was the only Frenchman left in the draw at Roland Garros.

Youzhny will next face either Briton Andy Murray, the fourth seed, or Czech 15th seed Tomas Berdych.

“It looks like it is a lesion on a stomach muscle,” Tsonga told reporters.

“I will have an MRI tomorrow to see exactly what it is.”

Tsonga felt pain even before entering the court and took no risks during training to preserve his chances against Youzhny.

“There is always a risk to aggravate when you play with some pain,” he said.

“But this event is too big for me to calculate. I wanted to give everything at my tournament, that is what I did and nobody will blame me for this.”

On another grey day in Paris, Tsonga hoped rain would save him.

“I told myself that if it could rain, it would maybe be better,” he said.

(Editing by Miles Evans)

Study sheds light on fundamental DNA repair mechanism

Washington, March 5 (ANI): A team of researchers has demonstrated for the first time the specific activity of the protein NEIL3, one of a group responsible for maintaining the integrity of DNA in humans and other mammals.

Since it was first identified about eight years ago, NEIL3 has been believed to be a basic DNA-maintenance enzyme of a type called a glycosylase.

These proteins patrol the long, twisted strands of DNA looking for lesions-places where one of the four DNA bases has been damaged by radiation or chemical activity.

They cut the damaged bases free from the DNA backbone, kicking off follow-on mechanisms that link in the proper undamaged base.

The process is critical to cell health, says National Institute of Standards and Technology (NIST) biochemist and Senior Research Fellow Miral Dizdaroglu.

“DNA is damaged all the time. About one to two percent of oxygen in the body becomes toxic in cells, for example, creating free radicals that damage DNA. Without these DNA repair mechanisms there wouldn”t be any life on this planet, really.”

The glycosylases seem to be highly specific; each responds to only a few unique cases of the many potential DNA base lesions. Figuring out exactly which ones can be challenging. NEIL3 and its kin NEIL1 and NEIL2 are mammalian versions of an enzyme found in the bacterium E. coli.

The lesion targets of NEIL1 and NEIL2 have been known for some time, but NEIL3, a much more complicated protein twice the size of the others, had resisted several attempts to purify it and determine just what it does.

In a significant advance, the research team managed to clone the house mouse version of NEIL3 (99 percent identical to the human variant), and then prepare a truncated version of it that was small enough to dissolve in solution for analysis but large enough to retain the portion of the protein that recognizes and excises DNA lesions.

Using a technique they developed for rapidly analyzing such enzymes, NIST researchers mixed the modified protein with sample DNA that had been irradiated to produce large numbers of random base lesions.

Because glycosylases work by snipping off damaged bases, a highly sensitive analysis of the solution after the DNA has been removed can reveal just which lesions are attacked by the enzyme, and with what efficiency.

The NIST results closely matched independent tests by others in the team that match the enzyme against short lengths of DNA-like strands with a single specific target lesion.

In addition to finally confirming the glycosylase nature of NEIL3, tests of the enzyme in a living organism-a tailored form of E. coli designed to have a very high mutation rate-had an unexpected bonus.

Measurements at NIST showed that NEIL3 is extremely effective at snipping out a particular type of lesion called FapyGua and seems to dramatically reduce mutations in the bacterium, a result that points both to the effectiveness of NEIL3 and the potentially important role of FapyGua in causing dangerous mutations in DNA. (ANI)

Natural hydrogel may boost spinal cord healing

Washington, Sep 18 (ANI): A jab of biomaterial gel into a spinal cord injury site may significantly improve healing, according to researchers at the Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center.

Dr. Mark Preul and Dr. Alyssa Panitch have found in a study that injection of an engineered hydrogel made up mainly of hyaluronic acid (a naturally-occurring body substance) into the spinal cord injury site decreases scarring, and promotes a realignment of the spinal cord fibres around the injury site.

The hyaluronic acid, which forms a scaffold-like configuration may help to structurally stabilize the spinal cord injury site.

The researchers traced cells in the brain stem after injury, and found much higher levels in the hydrogel treated animals as compared to animals that did not receive the treatment, and approached nearly normal levels.

Treated animals had higher functional scores than their non-treated counterparts.

“Spinal cord injury is devastating to civilian and military populations – especially to the young. There has been little progress toward paradigms of regeneration and few results that show real, sustained functional recovery. We’ve been so pre-occupied with regeneration, but that is a highly complicated and difficult to define goal. This project is a synergy of neurosurgeons and bioengineers that attempts repair of the SCI lesion cavity using a tissue-engineering biomaterials approach,” says Preul.

He added that the team aimed at finding ways to structurally allow the body to better heal itself.

“In this project we did not add anything to the hyaluronic acid. It may be that adding growth factors or cells into the gel matrix may allow even better results,” he said.

Preul said that the results show “we may be on a practical path that can give hope to the many people who suffer this sort of injury.”

The work was presented at the Annual Meeting of the American Association of Neurological Surgeons in San Diego where it won the Synthes Prize for Spine Research. (ANI)

Brain region responsible for our sense of personal space identified

London, August 31 (ANI): A new study led by neuroscientists at the California Institute of Technology (Caltech) may help improve the scientific understanding of the neural mechanisms involved in social behaviour, for it has pinpointed the brain structure that is responsible for our sense of personal space.

The rsearchers say that their findings may offer insight into autism, and other disorders where social distance is an issue.

The structure, the amygdala-a pair of almond-shaped regions located in the medial temporal lobes-was previously known to process strong negative emotions, such as anger and fear, and is considered the seat of emotion in the brain.

However, this is the first time that it has been linked rigorously to real-life human social interaction.

Ralph Adolphs, Bren Professor of Psychology and Neuroscience and professor of biology, and postdoctoral scholar Daniel P. Kennedy were able to make this link with the help of a unique patient, a 42-year-old woman known as SM, who has extensive damage to the amygdala on both sides of her brain.

“SM is unique, because she is one of only a handful of individuals in the world with such a clear bilateral lesion of the amygdala, which gives us an opportunity to study the role of the amygdala in humans,” Nature magazine quoted Kennedy, the lead author of the new report, as saying.

The researchers have revealed that SM has difficulty recognizing fear in the faces of others, and in judging the trustworthiness of someone, two consequences of amygdala lesions.

Adolphs, who has studied the patient for years, has also noticed that the very outgoing SM is almost too friendly, to the point of “violating” what others might perceive as their own personal space.

“She is extremely friendly, and she wants to approach people more than normal. It’s something that immediately becomes apparent as you interact with her,” says Kennedy.

Though previous studies on human subjects never revealed an association between the amygdala and personal space, the researchers knew from their knowledge of the lieterature that monkeys with amygdala lesions preferred to stay in closer proximity to other monkeys and humans than did healthy monkeys.

As part of their study, the researchers conducted an experiment in which the subject stands a predetermined distance from an experimenter, then walks toward the experimenter, and stops at the point where they feel most comfortable.

The chin-to-chin distance between the subject and the experimenter is determined with a digital laser measurer.

Among the 20 other subjects, the researchers observed that the average preferred distance was roughly two feet, while SM’s preferred distance was about one foot.

The team even observed that SM was at ease even at a nose-to-nose distance, and that her preferred distance didn’t change based on who the experimenter was and how well she knew them.

“Respecting someone’s space is a critical aspect of human social interaction, and something we do automatically and effortlessly. These findings suggest that the amygdala, because it is necessary for the strong feelings of discomfort that help to repel people from one another, plays a central role in this process. They also help to expand our understanding of the role of the amygdala in real-world social interactions,” Kennedy said.

The researchers later used a functional magnetic resonance imaging (fMRI) scanner to examine the activation of the amygdala in a separate group of healthy subjects who were told when an experimenter was either in close proximity or far away from them.

The subjects could not see, feel, or hear the experimenter while in the scanner, but still their amygdalae lit up when they believed the experimenter to be close by.

No such activity was detected when subjects thought the experimenter was on the other side of the room.

“It was just the idea of another person being there, or not, that triggered the amygdala,” Kennedy said.

He added: “(The Study shows that) the amygdala is involved in regulating social distance, independent of the specific sensory cues that are typically present when someone is standing close, like sounds, sights, and smells.”

He further said that the new findings might have relevance to studies of autism, a complex neurodevelopmental disorder that affects an individual’s ability to interact socially and communicate with others.

“We are really interested in looking at personal space in people with autism, especially given findings of amygdala dysfunction in autism. We know that some people with autism do have problems with personal space and have to be taught what it is and why it’s important,” he said.

Adding a word of caution, Kennedy also said: “It’s clear that amygdala dysfunction cannot account for all the social impairments in autism, but likely contributes to some of them and is definitely something that needs to be studied further.” (ANI)

Smoking may lead to brain damage in multiple sclerosis patients

Washington, Aug 18 (ANI): Cigarette smoking can cause brain damage in patients with multiple sclerosis (MS), according to a new study.

Scientists at the University at Buffalo have shown that MS patients who smoked for a little as six months during their lifetime had more destruction of brain tissue and more brain atrophy than the patients who never smoked.

“Cigarette smoking is one of the most compelling environmental risk factors linked to the development and worsening of MS,” said Dr Robert Zivadinov, UB professor of neurology, director of the Buffalo Neuroimaging Analysis Centre (BNAC) where the research was conducted and first author on the study.

“The biological basis of the potential link between smoking and MS has not yet been fully elucidated.

“In addition to nicotine, cigarette smoke contains hundreds of potentially toxic components, including tar, carbon monoxide and polycyclic aromatic hydrocarbons.

“In MS patients, smoking was associated with higher increased lesion burden and greater brain atrophy. Our results indicate that a wide range of quantitative brain MRI markers are affected by smoking in MS patients,” he added.

The study involved 368 patients from the Baird Multiple Sclerosis Center of the Jacobs Neurological Institute (JNI), where 128 had a history of smoking: 96 were active smokers who had smoked more than 10 cigarettes-per-day in the three months prior to the study start and 32 were former smokers who had smoked cumulatively for at least six months sometime in the past.

The remaining 240 participants were lifelong nonsmokers.

They found that that smokers with MS had a greater breakdown of the blood-brain barrier.

They had nearly 17 percent more brain lesions – patches of inflammation in the sheath surrounding the nerve fibres that impair their function – than nonsmokers with MS, and also had less brain volume.

Smoking also was associated with increased physical disability.

“The findings underscore the detrimental effect of smoking, providing a link between smoking and a more severe brain injury in MS patients,” said Dr Bianca Weinstock-Guttman, director of the Baird MS Center, UB associate professor of neurology and a principal co-author on the study.

The study appears in Neurology(r), the medical journal of the American Academy of Neurology. (ANI)

Jacko had cancerous lesion removed from nose weeks before death

Washington, July 4 (ANI): Late King of Pop Michael Jackson has a cancerous lesion removed from his nose just weeks before his death, says biographer Diane Dimond.

“Last week, I had two real sources call me and say he’s getting surgery right now for removal of skin cancer off his nose,” Usmagazine.com quoted Dimond as saying.

“This is not a man who suffers pain well. He likes painkillers. So he got some from here, he got some from there-who knows how much,” she added.

According to sources, the ‘Thriller’ hitmaker was also suffering from persistent insomnia in recent months.

“For the past 15 years, Michael always slept until 3 or 4 in the afternoon and was up all night. When he started rehearsals for the tour, it totally screwed up his system,” said a source.

The source added that Jackson began adding stimulants to his daily drug regimen in order to rise earlier. (ANI)

Novel MRI technique can lead to less breast biopsies in high-risk women

Washington, June 30 (ANI): Researchers from University of Wisconsin-Madison have suggested a new method, that when applied with MRI scans of the breast, can help rid women with increased breast cancer risk of the pain and stress of having to endure a biopsy of the lump or lesion.

It is recommended that women with certain breast cancer risk factors – including inherited genetic mutations, family or personal history of breast cancer, or previous radiation therapy to the chest should receive an annual MRI screening in addition to their yearly mammogram.

During a breast MRI, which lasts about a half hour, the technician injects a contrast agent into a vein in the patient’s arm.

The contrast agent flows throughout the body, including the breasts.

Because they are growing quickly, cancerous lesions often have immature vasculature, and the contrast agent flows in and “leaks” out quickly. Conversely, benign lesions show more gradual in and out flow.

“The tricky ones are the ones that enhance quickly and then fall off more slowly,” said Wally Block, a UW-Madison associate professor of biomedical engineering and medical physics.

“Many of these lesions turn out to be difficult to classify and lead to biopsy,” Block added.

The researchers suggest that right kind of MRI scan can help identify a cancerous lesion based on characteristics about its shape.

For instance, breaks or interruptions in a lesion can indicate a benign fibroadenoma. Lumps with smooth edges often are benign, while those with jagged edges can signal cancer.

With the new technique, an MRI machine acquires data radially and generates a high-resolution, three-dimensional image that radiologists can turn, slice and view from many perspectives – enabling them to study a lesion’s physical characteristics more carefully.

Machines equipped with the technique also acquire more data in less time. (ANI)

Drug-eluting stents found to be superior in efficacy to bare metal stents

London, May 7 (ANI): A study suggests that the use of drug-eluting stents on heart attack patients undergoing angioplasty is more effective and as safe as that of bare-metal stents.

Lead researcher Dr. Gregg W. Stone, a professor of medicine at Columbia University Medical Center/New York-Presbyterian Hospital, has revealed that in patients undergoing angioplasty, the use of paclitaxel-eluting stents has been found to reduce rates of target lesion revascularization (TLR) and binary angiographic restenosis when compared to the use of bare-metal stents after 1 year.

The study also revealed that the primary safety measure of major adverse cardiovascular events (MACE)-including death, reinfarction, stent thrombosis and stroke-established the non-inferiority of drug-eluting stents with respect to safety through 1 year.

The trial enrolled 3,602 heart attack patients at 123 centers in 11 countries, 3,006 of whom were randomised to paclitaxel-eluting stents versus otherwise identical bare metal stents.

During the trial, the use of paclitaxel-eluting stents resulted in a significant reduction of ischemia-driven target-lesion revascularization (TLR)-the rate at which a particular lesion re-narrows following stent implantation severely enough to require either a repeat angioplasty or bypass surgery operation-at 12 months.

The use of paclitaxel-eluting stents also resulted in a significant reduction in binary restenosis after 13 months, which is the rate at which the artery re-narrows at least 50 per cent following implantation of the stent, and was the secondary efficacy endpoint of the trial. The paclitaxel-eluting stent had a rate of 10 per cent and the bare metal stent had a rate of 22.9 per cent.

“Outcomes from prior registry and randomised trials of drug-eluting stents compared to bare metal stents in heart attack patients have been conflicting. These results now provide definitive evidence that paclitaxel-eluting stents are superior in efficacy to bare metal stents and have a comparable safety profile at 1 year,” said Dr. Stone.

The researchers believe that the findings of their study will have a major impact on how decisions are made regarding drug-eluting and bare metal stents in the highest risk patients, those in the early hours of a heart attack.

“This study removes much of the uncertainty and concern about the efficacy and safety of drug-eluting stents in this clinical setting. Moreover, all of the patients in this trial will be followed long-term to ensure that these favorable results are maintained,” said Dr. Stone.

A research article on the trial has been published in The New England Journal of Medicine. (ANI)

Drug-eluting stents found to be superior in efficacy to bare metal stents

Washington, May 7 (ANI): A study suggests that the use of drug-eluting stents on heart attack patients undergoing angioplasty is more effective and as safe as that of bare-metal stents.

Lead researcher Dr. Gregg W. Stone, a professor of medicine at Columbia University Medical Center/New York-Presbyterian Hospital, has revealed that in patients undergoing angioplasty, the use of paclitaxel-eluting stents has been found to reduce rates of target lesion revascularization (TLR) and binary angiographic restenosis when compared to the use of bare-metal stents after 1 year.

The study also revealed that the primary safety measure of major adverse cardiovascular events (MACE)-including death, reinfarction, stent thrombosis and stroke-established the non-inferiority of drug-eluting stents with respect to safety through 1 year.

The trial enrolled 3,602 heart attack patients at 123 centers in 11 countries, 3,006 of whom were randomised to paclitaxel-eluting stents versus otherwise identical bare metal stents.

During the trial, the use of paclitaxel-eluting stents resulted in a significant reduction of ischemia-driven target-lesion revascularization (TLR)-the rate at which a particular lesion re-narrows following stent implantation severely enough to require either a repeat angioplasty or bypass surgery operation-at 12 months.

The use of paclitaxel-eluting stents also resulted in a significant reduction in binary restenosis after 13 months, which is the rate at which the artery re-narrows at least 50 per cent following implantation of the stent, and was the secondary efficacy endpoint of the trial. The paclitaxel-eluting stent had a rate of 10 per cent and the bare metal stent had a rate of 22.9 per cent.

“Outcomes from prior registry and randomised trials of drug-eluting stents compared to bare metal stents in heart attack patients have been conflicting. These results now provide definitive evidence that paclitaxel-eluting stents are superior in efficacy to bare metal stents and have a comparable safety profile at 1 year,” said Dr. Stone.

The researchers believe that the findings of their study will have a major impact on how decisions are made regarding drug-eluting and bare metal stents in the highest risk patients, those in the early hours of a heart attack.

“This study removes much of the uncertainty and concern about the efficacy and safety of drug-eluting stents in this clinical setting. Moreover, all of the patients in this trial will be followed long-term to ensure that these favorable results are maintained,” said Dr. Stone.

A research article on the trial has been published in The New England Journal of Medicine. (ANI)

Nicotine chewing gums ‘raise cancer risk’

London, April 22 (ANI): A team of British scientists has found that nicotine chewing gum, lozenges and inhalers designed to help people to give up smoking may have the potential to cause cancer.

The research team, led by Muy-Teck Teh, of Queen Mary, University of London, has found a link between mouth cancer and exposure to nicotine, which may indicate that using oral nicotine replacement therapies for long periods could contribute to a raised risk of the disease.

In the study, researchers found that the effects of a genetic mutation that is common in mouth cancer can be worsened by nicotine in the levels that are typically found in smoking cessation products.

The results raise the prospect that nicotine, the addictive chemical in tobacco, may be more carcinogenic than had previously been appreciated.

“Although we acknowledge the importance of encouraging people to quit smoking, our research suggests nicotine found in lozenges and chewing gums may increase the risk of mouth cancer,” Times Online quoted Dr Teh as saying.

“Smoking is of course far more dangerous, and people who are using nicotine replacement to give up should continue to use it and consult their GPs if they are concerned. The important message is not to overuse it, and to follow advice on the packet,” Dr Teh added.

In the study, Dr Teh’s team investigated the role of a gene called FOXM1 in mouth cancer.

A mutation that raises the activity of this gene is commonly found in many tumours, and is also present in pre-cancerous cells in the mouth, the scientists found.

According to Dr Teh, this raised expression can then be worsened by exposure to nicotine.

“If you already have a mouth lesion that is expressing high levels of FOXM1 and you expose it to nicotine, it may add to the risk of converting it into cancer. Neither the raised FOXM1 nor nicotine is alone sufficient to trigger cancer, but together they may have an effect,” he said.

“The concern is that with smokers, you are looking at people who are already at risk of oral cancer. I’m worried that some may already have lesions they don’t know about in the mouth, and if they keep on taking nicotine replacement when they stop smoking products they will not be doing themselves any good,” he added.

The study is published in the journal Public Library of Science One. (ANI)

Genes raise melanoma risk even in those who tan easily

Washington, Apr 22 (ANI): The traditional risk factors for melanoma may not be as helpful in predicting risk in all people as previously thought, claims a new study.

The research has been presented at the American Association for Cancer Research 100th Annual Meeting 2009.

“Traditionally, a clinician might look at a person with dark hair who did not sunburn easily and classify them as lower risk for melanoma, but that may not be true for all people in the population,” said Peter Kanetsky, Ph.D., M.P.H., assistant professor of epidemiology at the University of Pennsylvania.

Kanetsky and his colleagues have identified that genetic variants in MC1R could help to predict melanoma risk in people who are not usually classified as high risk.

While this link previously has been observed, Kanetsky said it is now time to begin discussing genetic factors as part of the overall melanoma risk model.

For the current study, researchers analyzed 779 patients with melanoma from the Pigmented Lesion Clinic of the University of Pennsylvania and compared them with 325 healthy control patients.

Overall, the presence of certain MC1R variants was associated with a more than two-fold risk of melanoma, but this risk was largely confined to those patients who would not usually be considered to be at elevated risk.

Although those with dark hair are not thought to be at increased risk for melanoma, if they had dark hair and also inherited certain MC1R genetic variants, their risk for melanoma increased 2.4-fold. However, no elevated risk was associated with these same MC1R variants in those with blond or red hair.

MC1R was also associated with increased risk among those with dark eye color (3.2-fold increase), who did not freckle (8-fold increase), who tanned after repeated sun exposure (2.4 fold increase) or who tanned immediately without burning (9.5-fold increase). People with these characteristics are usually thought to be at reduced risk for melanoma.

Kanetsky said a clinical screening test for MC1R is not yet available. (ANI)

Novel technique uses stem cells to repair torn knee cartilage

London, Mar 25 (ANI): Scottish scientists are planning to test a new technique of “knitting together” torn knee tissue using stem cells in patients.

Professor Anthony Hollander said researchers hoped to mend torn knee cartilage – a common injury among young sportsmen and women.

It is being believed that the technique could prevent patients suffering serious knee problems, including osteoarthritis, for years to come.

Speaking at a Scottish Stem Cell Network conference in Edinburgh yesterday, Hollander, a Bristol University researcher, told scientists about the work.

The trials include patient tests of a stem cell technique to mend tears in the part of the knee cartilage known as the meniscus.

Hollander told The Scotsman: “At the moment, there’s no way to treat this (cartilage]. It is just cut out, and that leaves the patient very susceptible to osteoarthritis within a short number of years.”

He said the technique involves implanting stem cells on a membrane into the middle of the lesion and sewing it up.

“It is designed in a way that the cells will migrate across the lesion and literally knit it together. So, instead of growing new tissue, it’s healing the lesion itself,” he added.

The stem cells used will come from the patient’s own bone marrow, reducing the chance of them being rejected. (ANI)

Proteins that could yield predictive markers for pancreatic cancer identified

Washington, Mar 11 (ANI): Researchers at Fox Chase Cancer Center have identified a handful of proteins in incredibly tiny amounts that may one day help doctors distinguish between a harmless lesion in the pancreas and a potentially deadly one.

According to the researchers, these protein biomarkers, if confirmed in subsequent studies, could represent reliable indicators of pancreatic cancer or precancerous pancreatic lesions, which would allow for earlier, perhaps more successful, treatment.

“New technologies have become very good at identifying pancreatic cysts when they appear, but we know very little about how to categorize these cysts. We can detect, in as little as 40 microliters of cyst fluids a group of proteins that might collectively be used as indicators of a potentially cancerous cyst,” said the study’s senior author Anthony Yeung, Ph.D., molecular biologist and member of Fox Chase’s faculty.

Using an endoscopic ultrasound-guided technique, the researchers collected fluid from the cysts of 20 research participants with a small needle.

Yeung and his laboratory team then assayed the fluid to determine the number and type of proteins it contained. Identifying the proteins took more than eight months of continuous time with a mass spectrometer, an instrument that can determine the makeup of – and thereby identify – individual molecules.

Among the proteins they found were members of three families of proteins previously proposed to be biomarkers for pancreatic cancer, called mucins, CEACAMs, and S100s.

“From these samples we’ve identified a panel of these proteins that could all be considered harbingers of cancer in some way. Now that we know what we are looking for, we can use even more powerful spectrometry techniques to find this pattern of proteins fast enough that it could be used as part of a clinical service,” Yeung said.

Their findings appear in the March issue of the journal Pancreas. (ANI)

Stem cell therapy may help reverse paralysis

Washington, Jan 29 (ANI): Stem cells transplantation from the lining of the spinal cord, called ependymal stem cells, can reverse paralysis associated with spinal cord injuries in laboratory tests, a new study has found.

Results indicate that the population of these cells after spinal cord injury was many times greater than comparable cells from healthy animal subjects. The results open a new window on spinal cord regenerative strategies.

It was found that the transplanted cells proliferate after spinal cord injury and were recruited by the specific injured area.

On transplantation into animals with spinal cord injury, the stem cells regenerated ten times faster while in the transplant subject than similar cells derived from healthy control animals.

Spinal cord injury is a major cause of paralysis, and the associated trauma destroys numerous cell types, including the neurons that carry messages between the brain and the rest of the body.

In many spinal injuries, the cord is not actually severed, and at least some of the signal-carrying nerve cells remain intact. However, the surviving nerve cells may no longer carry messages because oligodendrocytes, which comprise the insulating sheath of the spinal cord, are lost.

The newly discovered regenerative mechanism was activated when a lesion formed in the injured area, following which the stem cells were found to have a more effective ability to differentiate into oligodendrocytes and other cell types needed to restore neuronal function.

Although, currently there are no effective therapies to reverse this disabling condition in humans, but the presence of these stem cells in the adult human spinal cords suggests that stem cell-associated mechanisms might be exploited to repair human spinal cord injuries.
“The human body contains the tools to repair damaged spinal cords. Our work clearly demonstrates that we need both adult and embryonic stem cells to understand our body and apply this knowledge in regenerative medicine.

There are mechanisms in our body which need to be studied in more detail since they could be mobilized to cure spinal cord injuries,” said Miodrag Stojkovic, co-author of the study.

The study is published in the journal Stem Cells. (ANI)